Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Nathan Pennell, MD, PhD, FASCO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Deputy Associate Director for Clinical Research
Case Comprehensive Cancer Center
Medical Oncologist, Department of Hematology and Oncology
Taussig Cancer Center, Cleveland Clinic 
Cleveland, Ohio

Disclosures

Nathan Pennell, MD, PhD, FASCO, has the following relevant financial relationships:
Consultant or advisor for: Genentech; Janssen; Lilly; Loxo Oncology; Merck; Mirati Therapeutics, Inc; Novartis; Pfizer, Inc.; ResistanceBio; Sanofi Genzyme
Research funding from: Altor; AstraZeneca; Genentech; Heat Biologics; Jounce Therapeutics; Loxo Oncology; Merck; Mirati Therapeutics, Inc.; Navire Pharma; Sanofi; Spectrum Pharmaceuticals; WindMIL Therapeutics

Sanja Dacic, MD, PhD

Professor of Pathology
Vice Chair and Director of Anatomic Pathology
Yale School of Medicine
New Haven, Connecticut

Disclosures

Sanja Dacic, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; AstraZeneca; Genentech; Merck; Takeda

Tina Cascone, MD, PhD

Assistant Professor
Thoracic Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Tina Cascone, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Arrowhead Pharmaceuticals, Inc.; AstraZeneca; Bristol Myers Squibb Company; EMD Serono, Inc.; Genentech; MedImmune, Inc.; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.
Research funding from: AstraZeneca; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; EMD Serono, Inc.; MedImmune, Inc.
Contracted researcher for: AstraZeneca; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; EMD Serono, Inc.; MedImmune, Inc.

Anne S. Tsao, MD

Vice-President Academic Affairs
Professor, Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Anne S. Tsao, MD, has the following relevant financial relationships:
Consultant or advisor for: Ariad Pharmaceuticals, Inc.; AstraZeneca; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; EMD Serono, Inc.; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer, Inc.; Roche; Seagen Inc.
Research funding from: Ariad Pharmaceuticals, Inc.; AstraZeneca; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Epizyme, Inc.; Genentech; Lilly; Merck; Millennium; Novartis; Polaris Group; Seagen Inc.

Editor

John Churchwell, PhD

Medical Education Director, Medscape, LLC

Disclosures

John Churchwell, PhD, has the following relevant financial relationships:
Formerly employed by an ineligible company: Medtronic, Inc

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC / CE

Early-Stage and Locally Advanced Non-Small Cell Lung Cancer Management

Authors: Nathan Pennell, MD, PhD, FASCO (Session Chair); Sanja Dacic, MD, PhD; Tina Cascone, MD, PhD; Anne S. Tsao, MD
CME / ABIM MOC / CE Released: 3/30/2023
Valid for credit through: 3/30/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 1.25 ABIM MOC points

Nurses - 1.25 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)

Pharmacists - 1.25 Knowledge-based ACPE (0.125 CEUs)

IPCE - 1.25 Interprofessional Continuing Education (IPCE) credit

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, surgeons (including surgical oncologists), pulmonologists, pathologists, nurses/nurse practitioners (NPs), and pharmacists.

The goal of this activity is for the learner to be better able to improve awareness of systemic therapies used to manage early-stage non-small cell lung cancer (NSCLC).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Role of biomarkers in the adjuvant/neoadjuvant settings
- Key data from clinical trials evaluating systemic treatment in patients with early-stage NSCLC
Have greater competence related to
- Tailoring therapy for patients with early-stage NSCLC
- Identifying potential treatment-related adverse events (TRAEs) in patients receiving therapy for early-stage NSCLC
Demonstrate greater confidence in their ability to
- Coordinate with other members of the interprofessional team to optimize outcomes for patients with early-stage NSCLC

Disclosures

Faculty

Nathan Pennell, MD, PhD, FASCO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Deputy Associate Director for Clinical Research
Case Comprehensive Cancer Center
Medical Oncologist, Department of Hematology and Oncology
Taussig Cancer Center, Cleveland Clinic 
Cleveland, Ohio

Disclosures

Nathan Pennell, MD, PhD, FASCO, has the following relevant financial relationships:
Consultant or advisor for: Genentech; Janssen; Lilly; Loxo Oncology; Merck; Mirati Therapeutics, Inc; Novartis; Pfizer, Inc.; ResistanceBio; Sanofi Genzyme
Research funding from: Altor; AstraZeneca; Genentech; Heat Biologics; Jounce Therapeutics; Loxo Oncology; Merck; Mirati Therapeutics, Inc.; Navire Pharma; Sanofi; Spectrum Pharmaceuticals; WindMIL Therapeutics

Sanja Dacic, MD, PhD

Professor of Pathology
Vice Chair and Director of Anatomic Pathology
Yale School of Medicine
New Haven, Connecticut

Disclosures

Sanja Dacic, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; AstraZeneca; Genentech; Merck; Takeda

Tina Cascone, MD, PhD

Assistant Professor
Thoracic Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Tina Cascone, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Arrowhead Pharmaceuticals, Inc.; AstraZeneca; Bristol Myers Squibb Company; EMD Serono, Inc.; Genentech; MedImmune, Inc.; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.
Research funding from: AstraZeneca; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; EMD Serono, Inc.; MedImmune, Inc.
Contracted researcher for: AstraZeneca; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; EMD Serono, Inc.; MedImmune, Inc.

Anne S. Tsao, MD

Vice-President Academic Affairs
Professor, Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Anne S. Tsao, MD, has the following relevant financial relationships:
Consultant or advisor for: Ariad Pharmaceuticals, Inc.; AstraZeneca; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; EMD Serono, Inc.; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer, Inc.; Roche; Seagen Inc.
Research funding from: Ariad Pharmaceuticals, Inc.; AstraZeneca; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Epizyme, Inc.; Genentech; Lilly; Merck; Millennium; Novartis; Polaris Group; Seagen Inc.

Editor

John Churchwell, PhD

Medical Education Director, Medscape, LLC

Disclosures

John Churchwell, PhD, has the following relevant financial relationships:
Formerly employed by an ineligible company: Medtronic, Inc

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Contact This Provider

For Nurses

Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) (Universal Activity Number: JA0007105-0000-23-085-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Early-Stage and Locally Advanced Non-Small Cell Lung Cancer Management

Authors: Nathan Pennell, MD, PhD, FASCO (Session Chair); Sanja Dacic, MD, PhD; Tina Cascone, MD, PhD; Anne S. Tsao, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/30/2023

Valid for credit through: 3/30/2024, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

How and When to Perform Biomarker Testing in the Era of Adjuvant/Neoadjuvant Targeted Treatments

Catch the rising tide on biomarker testing and targeted treatments with this winning presentation.
Sanja Dacic, MD, PhD

Adjuvant vs Neoadjuvant Therapy for Stage 2/3 Resectable NSCLC

Map out your therapeutic strategy with guidance from this exploration of adjuvant vs neoadjuvant therapy in stage 2/3 resectable NSCLC.
Tina Cascone, MD, PhD

Where Are We Going With Management of Unresectable Stage 3 NSCLC?

How can you manage unresectable Stage 3 NSCLC? Check out this insightful discussion to learn more.
Anne S. Tsao MD

Early-Stage and Locally Advanced Non-Small Cell Lung Cancer Management: Case Discussions

Think through how to approach the challenges of early-stage and locally advanced NSCLC with leaders in the field.
Nathan Pennell, MD, PhD, FASCO; Tina Cascone, MD, PhD; Sanja Dacic, MD, PhD; Anne S. Tsao, MD

Learning Feedback Questions

Please answer these questions to complement your learning experience.

Page 1 of 7

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Nathan Pennell, MD, PhD, FASCO

Sanja Dacic, MD, PhD

Tina Cascone, MD, PhD

Anne S. Tsao, MD

Editor

John Churchwell, PhD

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Early-Stage and Locally Advanced Non-Small Cell Lung Cancer Management

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Nathan Pennell, MD, PhD, FASCO

Sanja Dacic, MD, PhD

Tina Cascone, MD, PhD

Anne S. Tsao, MD

Editor

John Churchwell, PhD

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Early-Stage and Locally Advanced Non-Small Cell Lung Cancer Management

Contents of This CME Activity

How and When to Perform Biomarker Testing in the Era of Adjuvant/Neoadjuvant Targeted Treatments

Adjuvant vs Neoadjuvant Therapy for Stage 2/3 Resectable NSCLC

Where Are We Going With Management of Unresectable Stage 3 NSCLC?

Early-Stage and Locally Advanced Non-Small Cell Lung Cancer Management: Case Discussions

Learning Feedback Questions